Herriot Tabuteau - Mar 2, 2023 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
CHIEF EXECUTIVE OFFICER, Director, 10%+ Owner
Signature
/s/ Herriot Tabuteau, M.D.
Stock symbol
AXSM
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 05:16 PM
Previous filing
Mar 8, 2022
Next filing
Feb 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Employee Stock Option (Right to Buy) Award $0 +110K $0.00 110K Mar 2, 2023 Common Stock 110K $65.32 Direct F1
transaction AXSM Restricted Stock Units Award $0 +62.4K $0.00 62.4K Mar 2, 2023 Common Stock 62.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant.